Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest - 2Does physics say that free will doesn't exist?
- 3RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- 4Russian drone slams into block of flats in deadly wave of strikes across Kyiv
- 5Journey Lines for Each Explorer: Track down Your Ideal Journey
- SpaceX launches Starlink missions in dual-coast spaceflight doubleheader (videos)
- 5 Pizza Fixings That Characterize Your Character
- China’s new condom tax will prove no effective barrier to country’s declining fertility rate
- Turning into a Sharp Financial backer: Individual budget Wins
- The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures
- Land Rover Just Unveiled Its Dakar Rally Defender
- San Francisco sues 10 companies that make ultraprocessed food
- Germany paves the way for tighter EU asylum rules
- The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
